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SUMMARY – Asthma is a chronic infl ammatory disease that is characterized by reversible ob-
struction of airways, bronchial hyper-reactivity and airway remodeling. Th e etiology of asthma is 
multifactorial, with inheritance playing an important role. Th e aim of our study was to investigate the 
importance of biomarkers of asthma and the role of plasminogen activator inhibitor-1 (PAI-1) gene 
as a genetic factor that could be involved in the pathogenesis of asthma. Th e research was conducted 
at Jordanovac University Department for Lung Diseases and Croatian Institute of Transfusion 
 Medicine. Th e research included 149 patients with asthma and 89 healthy individuals. We collected 
demographic data of both study groups, determined asthma severity using GINA guidelines, and the 
values of biomarkers and PAI-1 by using laboratory techniques. Based on the results, we concluded 
that patients with allergic phenotype of asthma were younger, had better lung function and higher 
levels of IgE. By observing FeNO values, we were not able to distinguish asthmatic patients that had 
been diagnosed with obstruction of airways from asthmatic patients with normal lung function be-
cause FeNO indicates the infl ammatory component of disease. Th e 4G/5G polymorphism of PAI-1 
gene did not show any statistically signifi cant diff erence in the distribution of 4G/4G, 4G/5G and 
5G/5G between the group of asthmatic patients and control group.
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Introduction
Asthma is an infl ammatory disease of bronchial 
tubes characterized by bronchial hyper-reactivity and 
recurring episodes of airway obstruction. It is one of 
the most common chronic diseases worldwide, espe-
cially in children, and its incidence is increasing in de-
veloped countries1,2. According to the 100-year-old 
infl ammation theory, after analyzing the airways and 
lung parenchyma during autopsies of patients who 
died of asthma, a major cause of pathologic changes in 
asthma is chronic, non-infectious infl ammation of the 
airways3,4. Asthma is a serious and common disease 
caused by complex interaction of multiple genetic and 
environmental factors. Th e prevalence of asthma in the 
world is between 1% and 18%, depending on geo-
graphic area5. Asthma aff ects around 300 million peo-
ple worldwide and according to the growing preva-
lence, it is expected to aff ect 400 million people until 
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20206. Asthma aff ects people of all ages, but it most 
often starts during childhood (around 90% of all cas-
es), aff ecting more boys than girls. Th e incidence in 
female patients rises until adolescence and early adult-
hood, when it equalizes with the prevalence in men. By 
the age of 40, asthma aff ects more women than men. 
Asthma is more common in patients with other atopic 
diseases such as atopic dermatitis and allergic rhinitis7.
It is believed that asthma is the most common 
chronic disease in children in most developed coun-
tries, with a particularly high prevalence of up to 32% 
in the UK, New Zealand and Australia8. Croatia has 
determined the prevalence of asthma in children and 
adolescents of 6.02%-6.90% (depending on the age of 
children and the county)9.10, while the global preva-
lence of asthma in general population is 4.5%11. It is 
estimated that the global prevalence of asthma has a 
growing trend with the rate of 20% to 50% every ten 
years12. Recently, we observed a fl at-rate increase in 
asthma worldwide, at least in countries with high 
prevalence13, and it seems that further increase has 
been stopped14. Like most other chronic diseases, asth-
ma causes not only great fi nancial loss in health care 
systems, but also the general social one, due to the loss 
of many working hours (work or school absenteeism) 
with signifi cant impact on the quality of life15.
Atopy or inherited tendency to develop classic al-
lergic reaction is the most important known factor for 
the development of asthma. If both parents are atopic, 
the risk of the child to develop an allergic disease is 
40%-60%. If both parents and siblings are atopic, the 
risk is 80%. Despite the great progress in molecular 
biology, and considering multifactorial etiology, it may 
be diffi  cult to determine all the genes involved in the 
pathogenesis of asthma and atopy. To date, several 
studies have identifi ed many genes associated with 
asthma development, but localization of the IgE re-
ceptor (FcεRI) gene on chromosome 11q, cytokine 
gene on chromosome 5q and ADAM33 gene on chro-
mosome 20p13 drew biggest attention16-18. Patients 
with allergic asthma have elevated levels of IgE anti-
bodies directed against various environmental aller-
gens, and in such patients other atopic diseases such as 
allergic rhinitis, conjunctivitis, dermatitis, urticaria, 
food allergy and insect stings are frequently encoun-
tered. Th e most important inhaled allergens in severe 
asthma are dust mites, feathers, animal dander and 
mold, while in seasonal asthma the most important 
ones are pollen of trees, grass and weeds8.
Non-allergic asthma usually occurs after the age of 
thirty in patients without atopic tendency and with 
normal IgE concentration. Th e fi rst attack of adult on-
set asthma is often associated with viral infection of 
the upper respiratory tract.
Owing to the improvements and latest fi ndings in 
immunology and genetics, it will be easier to under-
stand the pathophysiology of asthma, defi ne biomark-
ers for its diagnosis and determine the potential treat-
ment targets19. Recent molecular and genetic studies 
suggest that inappropriate gene activation is pivotal in 
the induction of allergic reaction, as confi rmed by the 
gene expression changes upon specifi c imunotherapy20.
Plasminogen activator inhibitor-1 (PAI-1) is a 
single chain glycoprotein of approximate molecular 
weight of 50 kD, which regulates fi brinolytic system, 
preferably inhibiting tissue (tPA) and urokinase (uPA) 
plasminogen activator. Th e main function of PAI-1 is 
fi brinolysis reduction resulting in the accumulation of 
fi brin, and consequently elevation of PAI-1 plasma 
level that aff ects the normal degradation mechanism 
of fi brin and promotes thrombosis. According to re-
cent studies, rising concentration of PAI-1 leads not 
only to hypo-fi brinolysis, but decreases the activity of 
matrix metalloproteinases (MMP) and cell adhesion, 
playing a key role in tissue remodeling21. Due to its 
role in the coagulation cascade and infl ammation, it is 
associated with the development of various diseases 
such as deep venous thrombosis, atherosclerosis, endo-
metriosis, metabolic syndrome, breast cancer, etc. Th is 
fi nding prompted numerous studies on PAI-1 as a di-
agnostic marker for a number of diseases22. One of the 
characteristics of asthma is imbalance between MMP 
and their inhibitors, which contributes to remodeling 
of the airways and leads to the loss of lung function. 
PAI-1 contributes to the development of asthma by 
remodeling airways, bronchial hyper-reactivity and al-
lergic infl ammation. Activated mast cells are an im-
portant source of PAI-1 in tissue remodeling of the 
airways aff ected by infl ammation23.
In the promoter region of the PAI-1 gene, which is 
located on human chromosome 7q21.3-q22, the exis-
tence of a specifi c polymorphism 4G/5G aff ecting the 
expression of PAI-1 has been established. It is a poly-
morphism that includes deletion or insertion of gua-
nine base at -675 bp of the PAI-1 promoter gene. 
Studies have shown that people with homozygous 
4G/4G genotype have a signifi cantly higher concen-
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tration of PAI-1 than people with 5G/5G genotype, 
meaning that 5G allele is transcriptionally less active 
compared to 4G allele. In both 4G and 5G alleles, 
transcription activator can bind, but only the 5G allele 
can bind a transcription repressor24.
Th e aim of this study was dual: to assess the impact 
of biomarkers on the obstructive disorders of ventila-
tion and pathophysiology of allergic asthma; and to 
determine the frequency of 4G/5G polymorphism in 
the promoter region of the PAI-1 gene in patients 
with asthma and compare it with control group con-
sisting of people with no asthma and allergy symp-
toms.
Patients and Methods
Th e study was conducted at the Jordanovac De-
partment for Lung Diseases from February 2014 to 
April 2015. Th e study involved 149 adult patients with 
asthma. All patients were in a stable phase of the dis-
ease, without exacerbation, in good or partially good 
control of asthma on regular therapy adapted by Glob-
al Initiative for Asthma (GINA) guidelines.
Blood samples were collected along with the signed 
consent of the patient, which allows sampling for sci-
entifi c research. Control group consisted of healthy 
voluntary blood donors (N=89) from the City of Za-
greb and Zagreb County and employees of the Croa-
tian Institute of Transfusion Medicine. Control group 
subjects were in good health and had normal spirom-
etry values. Th e study was approved by ethics commit-
tees of the Jordanovac Department for Lung Diseases 
and Croatian Institute of Transfusion Medicine.
Patient parameters
Using medical records, we collected data on demo-
graphic characteristics of the patient group (gender, 
age, family history, data on smoking, comorbidities), 
need for urgent interventions, need for hospitalization, 
asthma phenotype (allergic vs. non-allergic) and nutri-
tional status expressed as body mass index (BMI, kg/
m2). Furthermore, all our patients underwent spirom-
etry and ventilatory dysfunction was diagnosed. Based 
on spirometry fi ndings, we estimated asthma severity 
according to the GINA guidelines25. We also mea-
sured IgE levels in serum, partial pressure of oxygen in 
arterial blood (pO2) and eosinophil count in sputum 
and nasal swab.
PAI-1 4G/5G polymorphism analysis
Blood samples were collected in BD Vacutainer 
tube with EDTA. Genomic high purity DNA is ex-
tracted from whole blood using the QIAamp DNA 
Blood Mini Kit on QIAcube device (Qiagen, Germa-
ny). Genotyping of -675 4G/5G PAI-1 polymorphism 
(rs1799889) was performed using the TaqMan SNP 
Genotyping Assay Custom for Serpin-1 by allelic dis-
crimination on the ABI 7500 real-time system device 
(Applied Biosystems, USA).
Statistical analysis
Asthma biomarker level of statistical signifi cance 
was set at 5% (p<0.05) and all confi dence intervals 
(CI) were calculated at the level of 95%. Th e normality 
of distribution of continuous variables (age, anthropo-
metric characteristics) was tested using Kolmogorov-
Smirnov test. Binary logistic regression was used for 
univariate and multivariate prediction of phenotype of 
allergic asthma and to predict obstruction (forced ex-
piratory volume, FEV 1 ≥80%); odds ratios (OR) with 
95% confi dence intervals (95% CI) were calculated for 
each variable. Th e variables that were signifi cantly as-
sociated in univariate analysis were included in the 
multivariate model. Statistical analysis was performed 
using the statistical package R, version 3.0.1 (R Devel-
opment Core Team).
On analyzing the results of PAI-1 genotyping we 
used statistical tests to compare independent categori-
cal data, as follows: χ2-test to determine the level of 
signifi cance of diff erences between the groups; and 
OR with 95% CI to assess the strength of connection 
between variables, or to assess the impact of PAI-1 
genotypes in the development of asthma.
Th e level of signifi cance was set at 0.05 in all analy-
ses and patient results were considered statistically sig-
nifi cant when p<0.05 compared to control group. We 
used the MedCalc software for data analysis.
Results
Th e study involved 149 patients in a stable phase of 
the disease and their demographic data are presented 
in Table 1. Th ere were 58 (38.9%) men and 91 (61.1%) 
women, average age 60. Th e mean BMI was 26.6 
(range, 23.3-30.1); 54 (36.2%) patients had normal 
body weight, 56  (37.6%) were overweight, and 39 
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Table 1. Demographic characteristics of study subjects 
(sex, age and BMI)








Age (yrs)* 60 40-70
BMI (kg/m2)* 26.6
normal (BMI <25.0) 54
overweight (BMI 25.0-29.9) 56





*Median (interquartile range); BMI = body mass index

































FEV1 (%)* 76.2 (56.1-90.1)




*Median (interquartile range); GINA classifi cation = Global Initia-
tive for Asthma (GINA); FEV = forced expiratory volume; FVC = 
forced vital capacity; FeNO = fractional exhaled nitric oxide; PEF = 
peak expiratory fl ow
(26.2%) were obese. Clinical parameters of patients are 
shown in Table 2. Based on diagnostic parameters, 68 
(45.6%) patients had non-allergic asthma, whereas 81 
(54.4%) patients had allergic asthma. In 81 (54.4%) 
patients, we did not fi nd airway obstruction (FEV1 
≥80%), whereas airfl ow limitation (FEV1 <80%) was 
recorded in 68 (45.6%) patients.
Based on spirometry results, we categorized asth-
ma severity according to GINA guidelines. Th ere were 
16 (10.7%) patients with occasional asthma (GINA I), 
27 (18.1%) with mild continuous asthma (GINA II), 
45 (30.2%) with moderately severe persistent asthma 
(GINA III) and 61 (40.9%) with severe persistent 
asthma (GINA IV). Th e mean laboratory value of IgE 
was 165 kU/L, while the mean value of fractional ex-
haled nitric oxide level (FeNO) was 19.4 ppb. Out of 
89 control subjects, 41 were male and 48 were female, 
average age 41 (23-65). Th e frequency of particular 
PAI-1-675 4G/5G genotypes in the group of patients 
with asthma and healthy control group is shown in 
Table 3. Analysis of genotyping results in the group of 
patients with asthma and control group using χ2-test 
showed no statistically signifi cant diff erences in the 
frequency of PAI-1 4G/5G genotypes between the 
two groups (p>0.05). OR and 95% CI for diff erent 
PAI-1 genotypes were not statistically signifi cant ei-
ther (Table 3). Th e frequency of 4G and 5G alleles in 
both groups is shown in Table 4. Th e frequency of 4G 
allele was 51.3% in patient group and 51.1% in control 
group. Th e frequency of 5G allele was 48.7% in patient 
group and 48.9% in control group. Th erefore, there was 
no statistically signifi cant diff erence in the frequency 
of 4G and 5G alleles between the group of patients 
with asthma and control group (p=0.9613).
Discussion
Asthma is a serious respiratory system disease that 
occurs because of complex interaction of multiple ge-
netic and environmental factors. Recent studies that 
investigated the infl uence of multiple genetic factors 
on asthma risk identifi ed several genes that might be 
involved in the pathogenesis of asthma, and one of 
them is PAI-1 gene. In this study, we assessed the sig-
nifi cance of asthma biomarker genes and the potential 
role of PAI-1 4G/5G polymorphism in the pathogen-
esis of asthma.
Our study results showed that patients with aller-
gic phenotype were of younger age, with better lung 
function, higher IgE level and higher FEV1 value, 
when compared to patients with non-allergic pheno-
type of asthma. Th e latter could be related to the fact 
that individuals with allergic phenotype respond better 
to inhaled corticosteroid treatment, or that those with 
non-allergic phenotype are basically elderly and have 
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Table 3. Results of PAI-1-675 4G/5G polymorphism genotyping in patient and control groups
PAI-1 
genotype





























Allele 4G 51.3 51.1
0.9613
Allele 5G 48.7 48.9
bronchi remodeled to a greater extent. Furthermore, 
our study showed that FeNO biomarker could not dis-
tinguish patients with impaired airway obstruction 
from those with normal pulmonary function, as it is 
known that it is an infl ammatory reaction marker, as 
well as a good indicator of asthma control.
A large number of patients with asthma are over-
weight, and adipose patients more often present with 
non-allergic asthma phenotype. Th ese results indicate 
that increased BMI could be of predictive value for dis-
ease development (together with other genetic factors), 
but not an objective characteristic of asthma itself.
Th e predominant feature of asthma is chronic in-
fl ammation which leads to bronchial hyper-reactivity, 
mucous hypersecretion and airway remodeling. PAI-1, 
a key inhibitor of fi brinolysis, takes part in all three of 
these complications of chronic airway infl amma-
tion25,26.
Statistical analysis of 4G/5G polymorphism fre-
quency in the promoter region of the PAI-1 gene did 
not show any statistically signifi cant diff erence in the 
frequency of 4G/4G, 4G/5G and 5G/5G genotypes 
between patients with asthma and control subjects. 
Th ere was no statistically signifi cant diff erence in the 
incidence of 4G and 5G alleles between these two 
groups either. In conclusion, we could not confi rm 
connection between the 4G/5G polymorphism in the 
promoter region of the PAI-1 gene with the develop-
ment of asthma in the study group. Results of our 
study coincide with previous studies in Caucasian 
populations, which did not confi rm a statistically sig-
nifi cant correlation between 4G/5G polymorphism 
and development of asthma, although it has been 
proven that PAI-1 has an important role in the patho-
genesis of asthma and that its level is increased in peo-
ple with 4G/4G genotype27. Further studies on a larg-
er population group are required, involving other po-
tential genetic risk factors for asthma development, 
apart from 4G/5G polymorphism, in order to deter-
mine whether there is a connection between genetic 
factors and development of asthma in the Croatian 
population.
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Sažetak
ZNAČENJE POLIMORFIZMA 4G/5G PAI-1 GENA I DIJAGNOSTIČKA VRIJEDNOST BIOČIMBENIKA 
U BOLESNIKA S ALERGIJSKIM I NEALERGIJSKIM FENOTIPOVIMA ASTME
M. Lampalo, I. Jukić, J. Bingulac-Popović, H. Safi ć, N. Ferara i S. Popović-Grle
Astma je kronična upalna bolest koju obilježava reverzibilna opstrukcija dišnih putova, bronhalna hiperreaktibilnost te 
remodelacija dišnih putova. Etiologija astme je multifaktorska, gdje nasljeđe ima važnu ulogu. Cilj našega rada bio je ispitati 
važnost biočimbenika astme i ulogu gena za inhibitor aktivatora plazminogena 1 (PAI-1) kao genetskog čimbenika koji bi 
mogao biti uključen u patogenezu astme. Istraživanje je provedeno u Klinici za plućne bolesti “Jordanovac” i Hrvatskom 
zavodu za transfuzijsku medicinu. U istraživanju je sudjelovalo 149 bolesnika sa stabilnom astmom i 89 zdravih davatelja 
krvi. Prikupili smo demografske podatke obiju skupina, odredili stupanj težine bolesti koristeći smjernice GINA te labora-
torijskim tehnikama odredili vrijednosti biomarkera (FeNO, IgE) i PAI-1 4G/5G polimorfi zma. Temeljem dobivenih rezul-
tata zaključili smo da su osobe s alergijskim fenotipom astme mlađe dobi, imaju bolju plućnu funkciju i više vrijednosti 
ukupnog IgE. Prema vrijednostima FeNO nismo mogli razlučiti astmatičare koje imaju dokazanu opstrukciju dišnih putova 
u odnosu na astmatičare s urednom plućnom funkcijom, budući da je FeNO pokazatelj upalne komponente bolesti. Polimor-
fi zam 4G/5G u promotorskoj regiji gena za PAI-1 kod bolesnika s astmom u usporedbi s ispitanicima kontrolne skupine 
pokazao je da ne postoji statistički značajna razlika u učestalosti genotipova 4G/4G, 4G/5G i 5G/5G između skupine obo-
ljelih od astme i skupine zdravih ispitanika.
Ključne riječi: Astma; Alergije; Biomarkeri; Aktivator plazminogena, inhibitor 1; Polimorfi zam, genetski
